Dr. Hassan Azhari, MD

Dr. Azhari practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Azhari's NPI, 1033729629, was assigned on August 7, 2020. Dr. Azhari graduated from American University of Beirut Faculty of Medicine in 2012. Dr. Azhari holds Minnesota license 66902.

Dr. Azhari's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Azhari's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Azhari practices. Vendor and product names are available with a free account.

Gastroenterology is Dr. Azhari's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Azhari is board certified in gastroenterology by the American Board of Internal Medicine. Dmand AI has Dr. Azhari's licenses on file in 6 states: Minnesota, Florida, New Jersey, Connecticut, New York and Pennsylvania.

Dmand AI lists acid reflux, cirrhosis of the liver, colonoscopy, fatty liver and upper GI endoscopy among the conditions Dr. Azhari treats.

CMS data shows 472 Medicare services from Dr. Azhari across 9 procedure codes in 2024, for 335 Medicare patients. Medicare paid $49,093 for them.

CMS counts 335 Medicare patients who saw Dr. Azhari in 2024. The largest group is 65 to 74, with 196 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 16% are also on Medicaid. Their average risk score is 2.62, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Azhari's median patient age at 69, with 50% women.

In 2024, Dr. Azhari wrote 300 Medicare Part D claims for 81 patients. 93% of them were for generic drugs. CMS names the drug for 252 of them, across 8 drugs with 11 or more claims each, at $10,910 in total drug cost. In 2023, CMS named 287 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. Azhari for performance year 2024, reported as part of a group. Dr. Azhari accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Azhari as offering telehealth. CMS counts 90 procedures of colonoscopy by Dr. Azhari, more than 77% of the clinicians it reports for that procedure.

Dmand AI links 10 papers to Dr. Azhari, published from 2018 to 2023. 2022 was the busiest year, with 3. The most frequent topics are Carcinoma, Hepatocellular, Immune Checkpoint Inhibitors and Immunotherapy. Dr. Azhari's most frequent co-authors are Ghassan K. Abou-Alfa, MD, Christopher H. Crane, MD and Carla Hajj, MD.

CMS Open Payments shows 9 general payments to Dr. Azhari from 3 drug and device companies from 2022 to 2025. Food and beverage make up the largest share, 67% of the total. Boston Scientific Corporation paid the most, $2,248.

Dr. Azhari graduated from American University of Beirut Faculty of Medicine in 2012. Dr. Azhari is a member of American Association for the Study of Liver Diseases (AASLD), ACG, Canadian Association for the Study of the Liver (CASL), Canadian Association of Gastroenterology (CAG) and European Association for the Study of the Liver (EASL).

Dr. Azhari is in network with 10 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.